USD
$0.00
(0.00%
)At Close (As of Oct 23, 2025)
$75.91M
Market Cap
-
P/E Ratio
-0.91
EPS
$8.32
52 Week High
$2.35
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | - |
| Total Revenue | $0 |
| Cost Of Revenue | $1.7M |
| Costof Goods And Services Sold | $1.7M |
| Operating Income | -$42M |
| Selling General And Administrative | $4.7M |
| Research And Development | $38M |
| Operating Expenses | $42M |
| Investment Income Net | - |
| Net Interest Income | $9M |
| Interest Income | $9.8M |
| Interest Expense | $807K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $1.7M |
| Income Before Tax | -$39M |
| Income Tax Expense | -$32K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$39M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$38M |
| Ebitda | -$36M |
| Net Income | -$39M |
| Field | Value (USD) |
|---|---|
| Total Assets | $199M |
| Total Current Assets | $175M |
| Cash And Cash Equivalents At Carrying Value | $173M |
| Cash And Short Term Investments | $173M |
| Inventory | - |
| Current Net Receivables | $858K |
| Total Non Current Assets | $25M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | - |
| Intangible Assets Excluding Goodwill | - |
| Goodwill | - |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | - |
| Other Current Assets | $1M |
| Other Non Current Assets | - |
| Total Liabilities | $17M |
| Total Current Liabilities | $15M |
| Current Accounts Payable | $2.2M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $10M |
| Total Non Current Liabilities | $1.7M |
| Capital Lease Obligations | - |
| Long Term Debt | - |
| Current Long Term Debt | $10M |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $10M |
| Other Current Liabilities | $912K |
| Other Non Current Liabilities | - |
| Total Shareholder Equity | $182M |
| Treasury Stock | - |
| Retained Earnings | -$91M |
| Common Stock | $273M |
| Common Stock Shares Outstanding | $30M |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | -$31M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $1.7M |
| Capital Expenditures | $1.3M |
| Change In Receivables | - |
| Change In Inventory | - |
| Profit Loss | - |
| Cashflow From Investment | -$1.3M |
| Cashflow From Financing | $10M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | - |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$39M |
| Field | Value (USD) |
|---|---|
| Gross Profit | - |
| Total Revenue | $0 |
| Cost Of Revenue | $1.7M |
| Costof Goods And Services Sold | $1.7M |
| Operating Income | -$42M |
| Selling General And Administrative | $4.7M |
| Research And Development | $38M |
| Operating Expenses | $42M |
| Investment Income Net | - |
| Net Interest Income | $9M |
| Interest Income | $9.8M |
| Interest Expense | $807K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $1.7M |
| Income Before Tax | -$39M |
| Income Tax Expense | -$32K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$39M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$38M |
| Ebitda | -$36M |
| Net Income | -$39M |
| Field | Value |
|---|---|
| Ex Dividend Date | 2021-07-15 |
| Declaration Date | None |
| Record Date | None |
| Payment Date | None |
| Amount | 2.5 |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
XBiotech Inc. is a transformative biopharmaceutical company based in Austin, Texas, specializing in the development of True Human monoclonal antibodies aimed at treating a range of diseases. Leveraging advanced technology to utilize human immune cells, the company seeks to create innovative and safer therapeutic options. With a diverse and promising pipeline, XBiotech is strategically positioned as a frontrunner in the biotherapeutics arena, committed to enhancing patient care and addressing significant unmet medical needs across multiple therapeutic areas.